Clinica Baviera (CBAV) AI Stock Analysis

• Market Cap: €748.33M
• Dividend Yield: 3.42%
• Average Volume (3M): 4.23K
• Price to Earnings (P/E): 18.4
• Beta (1Y): 0.42
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: ES
• Employees: 1,706
• Sector: Healthcare
• Sector Strength: 46
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 0.62
• Shares Outstanding: 16,307,580
• 10 Day Avg. Volume: 2,961
• 30 Day Avg. Volume: 4,234
• PEG Ratio: 1.07
• Price to Book (P/B): 5.24
• Price to Sales (P/S): 1.93
• P/FCF Ratio: 14.01
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €51.00
• Price Target Upside: 11.11% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0

• Rating: 76 Outperform
• Price Target: €51.00 ▲(11.11% Upside)

Clinica Baviera's strong financial performance, characterized by robust profitability and effective cash flow management, is the most significant factor driving the stock's score. The technical analysis supports a bullish outlook, although caution is advised due to potential overbought conditions. The valuation is fair, with a reasonable P/E ratio and an attractive dividend yield.

Clinica Baviera Business Overview & Revenue Model

Company Description

Clinica Baviera (CBAV) is a leading ophthalmology clinic specializing in vision correction treatments, including LASIK eye surgery, cataract surgery, and other refractive procedures. Established in Spain, the clinic has expanded its operations across several countries, providing high-quality eye care services. CBAV focuses on advanced technology and personalized patient care to deliver optimal results for those seeking to improve their vision.

How the Company Makes Money

Clinica Baviera generates revenue primarily through its surgical and medical services, including LASIK and cataract surgeries, as well as consultations and follow-up care. The clinic charges patients directly for these services, which are often covered by private health insurance plans. Additionally, CBAV may have partnerships with insurance companies that provide coverage for its procedures, further widening its patient base. The company also engages in marketing and promotional activities to attract new patients and foster brand loyalty, which plays a significant role in driving its revenue growth.

Clinica Baviera Financial Statement Overview

Summary

Clinica Baviera exhibits strong financial health, driven by consistent revenue and profit growth, a robust balance sheet with no debt, and efficient cash flow management. The company's financial statements reflect a well-managed enterprise with strong profitability and stable operations. While cash flow growth is moderate, the overall financial position is solid, providing a strong foundation for future growth.

Income Statement

Clinica Baviera has demonstrated strong and consistent revenue growth over the past years, with a Revenue Growth Rate of 16.74% from 2023 to 2024. The Gross Profit Margin for 2024 is robust at 88.37%, reflecting efficient cost management. The company also maintains healthy profitability with a Net Profit Margin of 15.31% and an EBIT Margin of 21.20%, indicating strong operational efficiency. However, there is room for improvement in EBITDA Margin, which stands at 29.73%.

Balance Sheet

The company's balance sheet is solid, with a Debt-to-Equity Ratio of 0.00 in 2024, showcasing no reliance on debt financing. The Equity Ratio is strong at 45.72%, indicating a well-capitalized structure. Return on Equity is impressive at 41.49%, reflecting effective use of shareholders' equity to generate profit. The balance sheet stability is a significant strength for Clinica Baviera.

Cash Flow

Clinica Baviera has shown consistent Free Cash Flow generation, with a Free Cash Flow to Net Income Ratio of 0.90 in 2024, indicating efficient conversion of net income into cash. The Operating Cash Flow to Net Income Ratio is healthy at 1.56, suggesting strong cash generation from operations. However, the Free Cash Flow Growth Rate is modest at 3.19%, indicating limited growth in cash flows compared to previous years.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	285.85M	262.65M	224.92M	198.45M	172.73M	122.63M
Gross Profit	229.76M	232.08M	197.85M	172.95M	151.25M	107.37M
EBITDA	80.46M	78.11M	67.22M	56.15M	53.49M	34.06M
Net Income	39.10M	40.20M	35.97M	29.52M	27.39M	13.94M
Balance Sheet
Total Assets	222.25M	211.95M	178.64M	150.10M	133.81M	120.92M
Cash, Cash Equivalents and Short-Term Investments	40.16M	38.58M	51.24M	38.99M	32.27M	26.94M
Total Debt	8.94M	63.47M	47.41M	39.98M	51.56M	54.84M
Total Liabilities	130.71M	113.59M	86.37M	81.74M	78.42M	76.02M
Stockholders Equity	90.54M	96.92M	91.00M	67.34M	54.60M	44.49M
Cash Flow
Free Cash Flow	42.11M	36.25M	35.13M	39.35M	36.28M	23.64M
Operating Cash Flow	66.88M	62.76M	57.81M	53.38M	46.86M	31.46M
Investing Cash Flow	-12.35M	-20.90M	-44.31M	-12.56M	-17.08M	-21.40M
Financing Cash Flow	-53.11M	-39.91M	-24.37M	-31.45M	-30.80M	-3.15M

Clinica Baviera Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 45.90
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ES:CBAV, the sentiment is Positive. The current price of 45.9 is above the 20-day moving average (MA) of 44.71, above the 50-day MA of 43.49, and above the 200-day MA of 36.42, indicating a bullish trend. The MACD of 0.69 indicates Negative momentum. The RSI at 61.82 is Neutral, neither overbought nor oversold. The STOCH value of 79.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ES:CBAV.

Clinica Baviera Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CBAV	76 Outperform	€748.33M	18.40		3.42%	―	―
Sector *	51 Neutral	$7.85B	-0.18	-40.01%	2.28%	22.97%	-2.05%
0K9H	―	€1.32B	12.40	14.89%	―	―	―
0RB1	―	€224.60M	35.71	3.04%	―	―	―
0R9G	―	€114.50M	11.55	31.66%	―	―	―
5P1	―	€207.62M	15.50		―	―	―
A2T	―	€214.26M	―	-11.64%	―	―	―

Clinica Baviera Corporate Events

Clínica Baviera Shareholders Approve Key Proposals at General Meeting

The Ordinary General Meeting of Shareholders of Clínica Baviera, S.A. approved all proposals by the Board of Directors, with 86.36% of the share capital represented. Key decisions included the approval of the annual accounts, management report, non-financial information statement, and sustainability report for 2024, as well as the re-election of Forvis Mazars Auditores as auditor for 2025. These approvals reflect strong shareholder support and are expected to positively impact the company’s governance and operational transparency.

Clínica Baviera Appoints New Vice Presidents to Board

Clínica Baviera has announced the appointment of Ms. Yongmei Zhang and Mr. Eduardo Baviera Sabater as vice presidents of its Board of Directors. This strategic leadership change is expected to enhance the governance structure of the company, potentially impacting its strategic direction and stakeholder engagement.